ImmunoPrecise Antibodies (IPA) Announces Q1 Fiscal 2025 Financial Results and Highlights

ImmunoPrecise Antibodies Ltd (IPA) (NASDAQ: IPA), a biotherapeutics research and technology company utilizing artificial intelligence, has reported its financial results for the first quarter of fiscal 2025, ending July 31, 2024. All figures are presented in Canadian dollars (CAD) unless…

Read MoreImmunoPrecise Antibodies (IPA) Announces Q1 Fiscal 2025 Financial Results and Highlights

Delcath Presents New Data on HEPZATO KIT™ Efficacy in Metastatic Uveal Melanoma at ESMO 2024

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company specializing in liver-targeted cancer therapies, announced new subgroup analysis data from the FOCUS Phase 3 trial of HEPZATO KIT™ (melphalan/Hepatic Delivery System) in patients with metastatic uveal melanoma (mUM). The data…

Read MoreDelcath Presents New Data on HEPZATO KIT™ Efficacy in Metastatic Uveal Melanoma at ESMO 2024

Cellworks Biosimulation Boosts IO Response Predictions in NSCLC Patients

Cellworks Group Inc., a leader in personalized therapy decision support and precision drug development, has announced promising results from a study using its computational biosimulation to predict immunotherapy (IO) responses in non-small cell lung cancer (NSCLC) patients. By combining biosimulation…

Read MoreCellworks Biosimulation Boosts IO Response Predictions in NSCLC Patients